Biacore and Bioreason Demonstrate Effectiveness Of Drug Binding Analysis Technology

PRESS RELEASE Code: 00/BIAC/14 For Immediate Release! For further information, please contact: Julian Abery, Vice President & Head of Pharmaceutical and Biotechnology Business Unit, Biacore AB +44 (0)7808 900732 Dr Bert Rietveld, Vice President Commercial Operations, Bioreason Inc +1 505 995 8188 Scientific/Trade Press Enquiries: Nikul Odedra, HCC.De Facto Group +44 (0) 207 496 3300 Biacore and Bioreason Demonstrate Effectiveness Of Drug Binding Analysis Technology th Uppsala, Sweden, and Santa Fe, NM, USA 6 September 2000.. Biacore International AB (Biacore) (SSE: BCOR; Nasdaq: BCOR) and Bioreason Inc. today presented positive first round results from a major alliance 1 aimed at enhancing ADME screening of small molecule compounds in late- stage drug discovery. The data demonstrates the successful integration of screening data from Biacore's novel SPR-based biosensor technology with Bioreason's predictive chemoinformatics software, to provide early and critical decision-making data on the binding of drug candidates to plasma proteins. The study, results of which were presented at the Society for Biomolecular Screening annual conference in Vancouver, Canada, showed that the integrated technologies were able to identify specific molecular groups with either positive or negative influence on compound binding to the major component of human plasma - human serum albumin (HSA). "Many candidate drugs fail at the drug lead optmization stage due to their unwanted binding to plasma proteins," explained Julian Abery, Biacore's Vice President and Head of the Pharmaceutical & Biotechnology Business Unit. "Biacore's technology can now provide high quality, detailed data on how drug lead candidates actually interact with specific plasma proteins. By linking our technologies we offer pharmaceutical companies the prospect of making far quicker, earlier and better judgements on drug candidate 2 selection, based on crucial compound pharmacophore protein binding data." Bert Rietveld, Vice President Commercial Operations at Bioreason, went on to explain that as well as enabling positive/negative drug selection, the technologies could also, "..provide powerful indicative data to help develop second generation leads through directed synthetic chemistry programs and rational drug design. The output from this research collaboration vindicates both companies' belief that by combining the strengths of our technologies and knowledge we can potentially develop data tools that could enhance the lead optimization process." Biacore and Bioreason initiated their alliance in September 1999. [Reuters: BCOR.N] - Ends - This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Notes to editors: 1 ADME, a key component of pharmacokinetics, stands for Absorption, Distribution, Metabolism and Excretion and represents the pharmaceutical characterization of new drug candidates. 2 A pharmacophore is the specific chemical site on a small molecule which interacts with the receptor site on the drug target. 3 Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. The company currently has five systems on ® the market with its BIACORE 3000 system offering specific application in drug discovery processes upstream of high-throughput screening (HTS). A new high-performance is currently under late-stage development and will focus on applications downstream of HTS. Based in Uppsala, Sweden, the company is listed on the OM Stockholm Exchange and Nasdaq in the U.S. In 1999 the company has sales of SEK 340.4 million and an operating income of SEK 67.6 million. Further information on Biacore can be found on the web: www.biacore.com Address and phone: Biacore International AB Rapsgatan 7, SE-754 50 Uppsala, SWEDEN Phone: +46 (0)18-675700 Fax: +46 (0)18-150111 info@biacore.com 4 Bioreason, located in Santa Fe, New Mexico, automates the reasoning of biologists and chemists to dramatically reduce the timeline and costs associated with the drug discovery process. 5 ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/09/06/20000906BIT00570/bit0001.doc http://www.bit.se/bitonline/2000/09/06/20000906BIT00570/bit0002.pdf

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com

Subscribe